Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999451 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
In front of a good diagnostic performance of all the 3 biomarkers in distinguishing negative biopsy vs. positive biopsy, the clinical benefit of using the PCA3 score and PHI to estimate prostatitis vs. PCa was comparable. PHI was the only determinant for prostatitis vs. BPH, whereas no biomarkers could differentiate prostate inflammation from HG-PIN.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Stefano M.D., Roberto Pharm.D., Ph.D., Cristian M.D., Enrico M.D., Susanna B.Sc., Roberto M.D., Antonino M.D., Donato M.D., Francesco M.D.,